In 86–90% of PDAC cases, tumors harbor activating mutations in the oncogene Kirsten rat sarcoma (KRAS) at codon 12, including G12D (45%), G12V (35%), G12R (17%), and G12C (1%–2%).[2, 3, 4] Studies have reported that KRAS mutations lead to an inactive GDP‐binding state in cancer. Here, KRAS is linked to cancer.